Amgen Files Lawsuit Against Roche For Patent Infringement

THOUSAND OAKS, Calif.--(BUSINESS WIRE)--Nov. 9, 2005--Amgen (NASDAQ:AMGN), the world's largest biotechnology company, today announced that it filed a lawsuit in the United States District Court in Boston, Massachusetts against F. Hoffmann-LaRoche Ltd., Roche Diagnostics GmbH, and Hoffmann-LaRoche, Inc., seeking a declaration by the Court that defendants' importation, use, sale or offer to sell a pegylated version of recombinant human erythropoietin infringe Amgen's patents. Amgen alleges infringement of six U.S. patents owned by Amgen that claim erythropoietin (EPO) products and pharmaceutical compositions, and processes for making EPO. Amgen seeks a permanent injunction preventing the defendants from making, importing, using, offering for sale or selling recombinant human EPO, including pegylated EPO, in the United States.

Back to news